Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.880
-0.010 (-0.53%)
At close: Apr 28, 2026, 4:00 PM EDT
1.840
-0.040 (-2.13%)
After-hours: Apr 28, 2026, 5:42 PM EDT
Inhibikase Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | 0.26 | 0.12 | 3.1 | |
| Revenue Growth (YoY) | - | - | 111.03% | -96.02% | 343.92% | |
| Cost of Revenue | - | - | 13.62 | 12.03 | 11.36 | |
| Gross Profit | - | - | -13.36 | -11.91 | -8.26 | |
| Selling, General & Admin | 23.56 | 11.38 | 6.73 | 6.22 | 6.51 | |
| Research & Development | 22.39 | 17.21 | - | - | - | |
| Operating Expenses | 45.95 | 28.59 | 6.73 | 6.22 | 6.51 | |
| Operating Income | -45.95 | -28.59 | -20.09 | -18.13 | -14.77 | |
| Interest Expense | - | - | - | - | -0.02 | |
| Interest & Investment Income | 3.72 | 1.07 | 1.06 | 0.07 | - | |
| EBT Excluding Unusual Items | -42.23 | -27.52 | -19.03 | -18.05 | -14.79 | |
| Asset Writedown | -7.4 | - | - | - | - | |
| Other Unusual Items | 1.37 | - | - | - | - | |
| Pretax Income | -48.26 | -27.52 | -19.03 | -18.05 | -14.79 | |
| Net Income | -48.26 | -27.52 | -19.03 | -18.05 | -14.79 | |
| Net Income to Common | -48.26 | -27.52 | -19.03 | -18.05 | -14.79 | |
| Shares Outstanding (Basic) | 98 | 24 | 6 | 4 | 3 | |
| Shares Outstanding (Diluted) | 98 | 24 | 6 | 4 | 3 | |
| Shares Change (YoY) | 314.60% | 293.35% | 42.74% | 39.15% | 121.72% | |
| EPS (Basic) | -0.49 | -1.16 | -3.16 | -4.28 | -4.87 | |
| EPS (Diluted) | -0.49 | -1.16 | -3.16 | -4.28 | -4.87 | |
| Free Cash Flow | -27.8 | -19.15 | -18.1 | -17.59 | -14.3 | |
| Free Cash Flow Per Share | -0.28 | -0.81 | -3.00 | -4.17 | -4.71 | |
| Gross Margin | - | - | - | - | -266.35% | |
| Operating Margin | - | - | -7711.98% | -14686.17% | -476.23% | |
| Profit Margin | - | - | -7304.73% | -14625.86% | -476.88% | |
| Free Cash Flow Margin | - | - | -6947.87% | -14253.37% | -461.10% | |
| EBITDA | -45.89 | -28.56 | -19.91 | -18.12 | - | |
| D&A For EBITDA | 0.06 | 0.03 | 0.18 | 0.01 | - | |
| EBIT | -45.95 | -28.59 | -20.09 | -18.13 | -14.77 | |
| Revenue as Reported | - | - | 0.26 | 0.12 | 3.1 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.